Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:FEMY

Femasys Q3 2026 Earnings Date & Estimates

Femasys logo
$1.50 0.00 (0.00%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$1.53 +0.03 (+2.00%)
As of 04:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Femasys is estimated to report Q3 2026 earnings on Tuesday, November 17, 2026. The conference call is scheduled for November 13, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Femasys in Q3 2026

Femasys is expected to post earnings of -$0.47 per share on revenue of $0.76 million. In the same quarter a year earlier Femasys reported -$2.00 per share on revenue of $0.73 million. Femasys last reported on August 14, 2026, posting -$1.33 per share and missing the -$1.31 consensus estimate. Femasys has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.47
Expected Revenue
$0.76 million
Prior-Year EPS
-$2.00
Prior-Year Revenue
$0.73 million
Expected Revenue Growth
+4.6%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.33 (Missed by -$0.02)
Last Quarter Revenue
$0.33 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Femasys Q3 2026 Earnings FAQ

Femasys (NASDAQ:FEMY) is estimated to report Q3 2026 earnings on Tuesday, November 17, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Femasys' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Femasys to post earnings of -$0.47 per share for Q3 2026.

The consensus revenue estimate for Femasys is $0.76 million for Q3 2026.

Femasys Earnings Headlines

Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs
October 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/20/3384450/0/en/femasys-partners-with-sandsrx-pharmacy-to-support-femaseed-fertility-portfolio-launch-to-ob-gyns.html
Femasys (NASDAQ:FEMY) Stock Rating Upgraded by Wall Street Zen
October 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31127107
Forget the AI predictions. Look at the income
AI predictions are everywhere, but Tim Plaehn is focused on something concrete: income. He's found a small AI fund paying investors every single Thursday, up to $1,051 a month. While others debate AI's future, this fund is already paying out now.tc pixel
October 26 at 1:00 AM  |  Investors Alley (Ad)
Femasys Doubles Enrollment Sites For FemBloc Pivotal Study; Stock Down
October 14, 2026  |  rttnews.comhttps://www.rttnews.com/3698992/femasys-doubles-enrollment-sites-for-fembloc-pivotal-study-stock-down.aspx
Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control
October 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/14/3380761/0/en/femasys-doubles-enrolling-sites-in-fembloc-finale-pivotal-trial-for-non-surgical-permanent-birth-control.html
Femasys: Launch Is Funded. If The Sales Force Delivers, Then The Company Is In Tall Cotton.
October 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4953966-femasys-stock-launch-funded-if-sales-force-delivers-then-company-in-tall-cotton
See More Femasys Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Femasys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Femasys and other key companies, straight to your email.

About Femasys

Femasys (NASDAQ:FEMY) is a biomedical company focused on developing and commercializing therapies and technologies for women’s health. The company’s products are designed to address reproductive health needs, including contraception and infertility, through minimally invasive procedures intended to be performed in a physician’s office.

Femasys’ product portfolio includes FemaSeed, an FDA-cleared intratubal insemination system designed to deliver sperm directly into the fallopian tube during an infertility treatment procedure. The company is also developing FemBloc, a non-surgical, investigational permanent birth-control system intended to provide a hormone-free contraceptive option. FemBloc has not been approved for commercial use in the United States.

Headquartered in Atlanta, Georgia, Femasys was founded by Kathy Lee-Sepsick, who serves as the company’s president and chief executive officer. The company primarily develops its products for the U.S. market and has pursued regulatory and commercial opportunities in women’s reproductive health.

View Femasys Profile
Earnings Tools